Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02946034 · ClinicalTrials.gov registry record · Phase 4

Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C

A Phase 4 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 4
Development phase
10
Enrollment target

NCT02946034: Completed Phase 4 study, sponsored by Massachusetts General Hospital.

NCT02946034 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02946034, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 4
Development phase
10 participants
Enrollment target

Study Summary

Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.

Primary Outcome

Measure of novel biomarkers of incident and progressive CKD and liver disease to determine if eradication of HCV infection changes the measures of chronic inflammation associated with progressive end-organ disease. To calculate the average change, the difference between baseline values and the average of 12-weeks post treatment and 40-weeks post treatment were found for each patient. These differences were then averaged, as shown below.

Interventions

  • DRUG Mavyret
  • DRUG Viekira Pak ± ribavirin

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2017-02-01
Est. Completion 2020-09-16
Phase Phase 4
Massachusetts General Hospital

2,032 total trials

What the finished NCT02946034 record still lists

NCT02946034 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Mavyret is the first listed.

NCT02946034 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02946034 about?

NCT02946034 is a clinical study titled "Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C". Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.

What is the current status of trial NCT02946034?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2017-02-01. Estimated completion is 2020-09-16.

What interventions are being tested in trial NCT02946034?

The interventions under investigation include: Mavyret (DRUG), Viekira Pak ± ribavirin (DRUG).

Who is sponsoring clinical trial NCT02946034?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02946034's enrollment target sits among peer trials

10 1940th of 2000 higher than 33 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02946034, the US trial registry maintained by the National Library of Medicine. NCT02946034 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.